Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Nature Publishing Group full text link Nature Publishing Group Free PMC article
Full text links

Actions

Share

Review
.2017 Jul;14(7):399-416.
doi: 10.1038/nrclinonc.2016.217. Epub 2017 Jan 24.

Tumour-associated macrophages as treatment targets in oncology

Affiliations
Review

Tumour-associated macrophages as treatment targets in oncology

Alberto Mantovani et al. Nat Rev Clin Oncol.2017 Jul.

Abstract

Macrophages are crucial drivers of tumour-promoting inflammation. Tumour-associated macrophages (TAMs) contribute to tumour progression at different levels: by promoting genetic instability, nurturing cancer stem cells, supporting metastasis, and taming protective adaptive immunity. TAMs can exert a dual, yin-yang influence on the effectiveness of cytoreductive therapies (chemotherapy and radiotherapy), either antagonizing the antitumour activity of these treatments by orchestrating a tumour-promoting, tissue-repair response or, instead, enhancing the overall antineoplastic effect. TAMs express molecular triggers of checkpoint proteins that regulate T-cell activation, and are targets of certain checkpoint-blockade immunotherapies. Other macrophage-centred approaches to anticancer therapy are under investigation, and include: inhibition of macrophage recruitment to, and/or survival in, tumours; functional re-education of TAMs to an antitumour, 'M1-like' mode; and tumour-targeting monoclonal antibodies that elicit macrophage-mediated extracellular killing, or phagocytosis and intracellular destruction of cancer cells. The evidence supporting these strategies is reviewed herein. We surmise that TAMs can provide tools to tailor the use of cytoreductive therapies and immunotherapy in a personalized medicine approach, and that TAM-focused therapeutic strategies have the potential to complement and synergize with both chemotherapy and immunotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. A schematic representation of the role of tumor-associated macrophages in tumor progression.
Panel A. Monocytes and MoMDSC (see Box 1) are recruited in tumors in response to diversechemoattractants including CSF1, chemokines and complement components. Intumors, monocytes differentiate into macrophages (Tumor-associated macrophages,TAM). In some tumors, in situ proliferation may occur and local tissue residentmacrophages of embryonic origin may contribute to TAM. Signals in the tumormicroenvironment skew the function of TAM.Panel B. Pathways and molecules polarizing TAM differ indifferent tumors. These include: IL-4 and IL-13 derived from TH2 cells,eosinophils (Eos) and basophils (Bas); cytokines and metabolites from tumorcells; antibodies (Ab) from B cells and immune complexes (Ic); stromalcell-derived factors (IL-1, LT).Panel C. TAM affect virtually all aspects of tumor cell biology,including provision of a niche for cancer stem cells (CSC); angiogenesis;epithelial to mesenchymal transition (EMT); invasion and metastasis;proliferation; genetic instability.
Figure 2
Figure 2. Bimodal function of TAM in response to chemotherapy and radiotherapy.
Macrophages orchestrate immune responses that can either hamper (left) or foster(right) the effectiveness of conventional anticancer strategies. On the left: cytotoxic agents enhance tumor infiltration by immunosuppressivemacrophages, which activate chemoprotective T cells and tame adaptive immuneresponses; chemotherapy or radiotherapy-induced tissue damage triggers therecruitment of immunosuppressive myeloid cells, which orchestrate a misdirectedtissue-repair response, promoting tumor growth and revascularization;macrophages, an essential component of tissue stem cell niches, can protect CSCagainst cytotoxicity. On the right: selected chemotherapeutic agents (e.g Doxorubicin) increase theimmunogenicity of malignant cells (immunogenic cell death), which stimulatemyeloid cells to differentiate into antigen presenting cells and triggereffective adaptive immune responses; anticancer agents like Gemcitabine candirectly skew macrophage effector functions towards an antitumor mode andincrease their cytotoxicity, resulting into a favorable synergism; neoadjuvantslow-dose γ-irradiation set macrophage functions in an antitumor mode,promoting regression at sites distant from irradiated lesions (abscopal effect).CSC: cancer stem cells.
Figure 3
Figure 3. Schematic representation of strategies targeting macrophages in tumor settings.
Macrophage-centered therapeutic approaches are aimed either at activating theirantitumor activity (Panel A) or inhibiting their recruitment and functionsrelated to tumor promotion (panel B).Panel A: the concerted action of microbial moieties (acting viaTLRs) and IFNγ induces M1-like functional polarization and can activatemacrophage killing of tumor cells; macrophage-mediated antibody-dependentcytotoxicity (ADCC) can mediate the therapeutic effect of therapeuticantibodies; interference with the SIRPα-CD47 pathway activatesmacrophage-mediated antibody-dependent phagocytosis (ADCP) and results infunctional skewing of macrophages in an M1 direction and antitumor activity; ananti-CD40 antibody re-educates M2-like macrophages in the tumormicroenvironment, leading to re-establishment of tumor immune surveillance.Panel B: Inhibition of monocyte-attracting molecules, includingchemokines (e.g CCL2, CCL5), VEGF, CSF-1 and complement mediators (C5a) withspecific monoclonal antibodies (e.g. carlumab, emactuzumab) or antagonists (e.g.maraviroc) prevent macrophage recruitment to the tumor microenvironment,reducing tumor growth and dissemination; inhibitors of CSF-1 have also thepotential to inhibit macrophage survival; Trabectedin activates acaspase-dependent pathway of apoptosis, selectively in cells of the monocytelineage, causing a partial depletion of circulating monocytes and TAM; theprotective function of NAIDS, aspirin in particular, against primary cancer andmetastasis relies on the inhibition of prostaglandin production, which haveimmunosuppressive properties; TAM contribute to suppression of adaptive immunityby expression of immunosuppressive molecules, such as IDO, cyclooxygenases(COX1,2), TGFβ and IL-10. Moreover, TAM express triggers of checkpointblockade, such PD-L1, PD-L2, B7H4 and VISTA. TLR: Toll-like receptors; IFNRα: interferon receptor alpha; FcR: Fcreceptor, mAb: monoclonal antibody; VEGF: vascular endothelial growth factor;CSF-1: colony-stimulating factor; NAIDS: nonsteroidal anti-inflammatory drugs;IDO: indoleamine 2,3 dioxygenase; TGFβ: transforming growth factorβ; IL-10: interleukin 10.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44. - PubMed
    1. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339:286–91. - PMC - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. - PubMed
    1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45. - PubMed
    1. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–7. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Nature Publishing Group full text link Nature Publishing Group Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp